Compare GHRS & TWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHRS | TWO |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Ireland | United States |
| Employees | N/A | 486 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 1.3B |
| IPO Year | 2021 | N/A |
| Metric | GHRS | TWO |
|---|---|---|
| Price | $22.53 | $12.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | ★ $41.38 | $12.56 |
| AVG Volume (30 Days) | 213.0K | ★ 2.4M |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.77% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.67 | $8.84 |
| 52 Week High | $24.66 | $14.17 |
| Indicator | GHRS | TWO |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 67.27 |
| Support Level | $12.52 | $9.53 |
| Resistance Level | $22.88 | $12.70 |
| Average True Range (ATR) | 1.41 | 0.17 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 70.20 | 71.54 |
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.